A Case of Methimazole-Resistant Severe Graves’ Disease: Dramatic Response to Cholestyramine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
A 22-year-old woman with severe Graves’ disease was referred from a local clinic because of her refractory hyperthyroidism. She presented with exophthalmos, diffuse goiter, and tachycardia. She was treated with a maximal dose of methimazole and a beta-blocker for 2 months. However, her thyroid function test (TFT) did not improve. TFT showed a free T4 level of 74.7 ng/dL and a thyroid stimulating hormone (TSH) level of 0.007 μIU/mL. She was then administered cholestyramine (4 g thrice daily), hydrocortisone (300 mg/day) and methimazole (100 mg/day) which prepared the patient for surgery by reducing the free T4 level (4.7 ng/dL). The patient underwent a total thyroidectomy without experiencing thyrotoxic crisis. This case describes the use of cholestyramine for the first time in Korea in treating Graves’ disease and provides limited evidence that cholestyramine can be an effective option.
Abstract
A 22-year-old woman with severe Graves’ disease was referred from a local clinic because of her refractory hyperthyroidism. She presented with exophthalmos, diffuse goiter, and tachycardia. She was treated with a maximal dose of methimazole and a beta-blocker for 2 months. However, her thyroid function test (TFT) did not improve. TFT showed a free T4 level of 74.7 ng/dL and a thyroid stimulating hormone (TSH) level of 0.007 μIU/mL. She was then administered cholestyramine (4 g thrice daily), hydrocortisone (300 mg/day) and methimazole (100 mg/day) which prepared the patient for surgery by reducing the free T4 level (4.7 ng/dL). The patient underwent a total thyroidectomy without experiencing thyrotoxic crisis. This case describes the use of cholestyramine for the first time in Korea in treating Graves’ disease and provides limited evidence that cholestyramine can be an effective option.
참고문헌 (15)
- Ginsberg J, "Diagnosis and management of Graves' disease", CMAJ, 168(5), pp.575~585 (2003)
- Ma C, "Radioiodine therapy versus antithyroid medications for Graves' disease", Cochrane Database Syst Rev, 2, pp.CD010094~ (2016)
- Pearce EN, "Diagnosis and management of thyrotoxicosis", BMJ, 332(7554), pp.1369~1373 (2006)
- Solomon BL, "Adjunctive cholestyramine therapy for thyrotoxicosis", Clin Endocrinol (Oxf), 38(1), pp.39~43 (1993)
- Mercado M, "Treatment of hyperthyroidism with a combination of methimazole and cholestyramine", J Clin Endocrinol Metab, 81(9), pp.3191~3193 (1996)
- Sebastian-Ochoa A, "Dramatic response to cholestyramine in a patient with Graves' disease resistant to conventional therapy", Thyroid, 18(10), pp.1115~1117 (2008)
- Romaldini JH, "Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism", J Clin Endocrinol Metab, 57(3), pp.563~570 (1983)
- Tomaski SM, "Sodium ipodate (oragrafin) in the preoperative preparation of Graves' hyperthyroidism", Laryngoscope, 107(8), pp.1066~1070 (1997)
- Tallstedt L, "Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group", N Engl J Med, 326(26), pp.1733~1738 (1992)
- Traisk F, "Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131", J Clin Endocrinol Metab, 94(10), pp.3700~3707 (2009)
- Northcutt RC, "The influence of cholestyramine on thyroxine absorption", JAMA, 208(10), pp.1857~1861 (1969)
- Tsai WC, "The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism", Clin Endocrinol (Oxf), 62(5), pp.521~524 (2005)
- Kaykhaei MA, "Low doses of cholestyramine in the treatment of hyperthyroidism", Endocrine, 34(1-3), pp.52~55 (2008)
- Li H, "A hyperthyroid patient with Graves' disease who was strongly resistant to methimazole: investigation on possible mechanisms of the resistance", Endocr J, 42(5), pp.697~704 (1995)
- 양여리, "Refractory Graves’ Disease Successfully Cured by Adjunctive Cholestyramine and Subsequent Total Thyroidectomy", Endocrinology and Metabolism, 30(4), pp.621~626 (2015), 대한내분비학회